NexImmune Announces Melanoma Research Collaboration with NYU Langone's Perlmutter Cancer Center

GAITHERSBURG, MD, March 14, 2022 -- NexImmune, Inc. , a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by... | March 14, 2022

Related Keywords

Chad ,Jeffrey Weber ,Jeffreys Weber ,Kristi Jones ,Langone Health ,National Cancer Institute ,Isaac Perlmutter Cancer Center ,Cancer Center ,Nasdaq ,Exchange Commission ,Neximmune Inc ,Corporate Affairs ,Comprehensive Cancer Center ,Deputy Director ,Chief Executive Officer ,Artificial Immune Modulation ,Scientific Advisory Board ,Private Securities Litigation Reform Act ,Annual Report ,Neximmune ,Nc Stock Exchange ,News ,Information ,Press Release ,Arch ,022 ,Biotechnology ,Company ,Developing ,Novel ,Approach ,O ,Immunotherapy ,Esigned ,Orchestrate ,Argeted ,Immune ,Esponse Nexi Us65344d1090 ,